PROVENTIL-HFA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROVENTIL-HFA (PROVENTIL-HFA).
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
| Metabolism | Metabolized primarily by conjugation (sulfation) in the liver, not significantly by CYP450 enzymes. |
| Excretion | Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment. |
| Protein binding | Approximately 50-60% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 2-3 L/kg. Indicates extensive distribution into tissues, including lungs and skeletal muscle. |
| Bioavailability | Inhalation: 10-20% of the dose reaches the lungs systemically; the remainder is swallowed and undergoes first-pass metabolism. |
| Onset of Action | Inhalation: 5-15 minutes. Oral inhalation produces rapid bronchodilation within 5-15 minutes. |
| Duration of Action | Inhalation: 4-6 hours. Bronchodilation effect wanes after 4-6 hours; regular use may lead to tolerance. |
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No specific dose adjustment required; drug is predominantly hepatically metabolized and renally excreted unchanged in negligible amounts. Use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C, consider reduced frequency due to potential accumulation; clinical monitoring advised. |
| Pediatric use | Children 4 years and older: 2 inhalations (90 mcg each) every 4 to 6 hours as needed. For exercise-induced bronchospasm: 2 inhalations 15 to 30 minutes before exercise. For children <4 years: safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment; elderly patients may have increased sensitivity. Monitor for cardiovascular effects and paradoxical bronchospasm. Start at lower end of dosing range if concurrent disease or other medications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROVENTIL-HFA (PROVENTIL-HFA).
| Breastfeeding | Albuterol is excreted into breast milk. M/P ratio unknown. Systemic absorption from inhaled doses is minimal. No known adverse effects in breastfed infants. Caution advised; use only if clearly needed. |
| Teratogenic Risk | FDA Pregnancy Category C. In animal studies, albuterol showed teratogenic effects (cleft palate) at high doses. Adequate human studies are lacking. Inhaled albuterol is not associated with major congenital malformations. Use only if clearly needed, balancing risk of uncontrolled asthma which poses greater fetal risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["History of hypersensitivity to albuterol or any component of the formulation"]
| Precautions | ["Excessive use may lead to paradoxical bronchospasm","Cardiovascular effects (tachycardia, arrhythmia) in susceptible patients","Hypokalemia with high doses","Immediate hypersensitivity reactions (urticaria, angioedema, rash)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal respiratory status, heart rate, and blood pressure. Assess fetal heart rate and uterine activity, especially in preterm labor. In pregnancy with comorbid conditions, consider periodic ultrasound for fetal growth. |
| Fertility Effects | No significant adverse effects on fertility in animal studies. In humans, no data indicating impairment of fertility. |